Scale out: trim 25% now at market, another 25% on any push above $87, keep a small position for value/catalyst optionality. Widen stop to 2 ATR below entry (~$83.50-$84) to allow position to breathe through normal volatility rather than exiting prematurely on daily noise.

• Bearish technical setup is real: price below all MAs, RSI at 23, MACD accelerating negative, 200 SMA breached intraday at $84.50, capitulation volume September 18 at 21 million shares
• Q2 2026 actual results: EPS $2.31, revenue +7.3% YoY, FCF $5.65 billion (strongest quarter in visible window)
• 2027 headwind creates multiple discount but doesn't erase 2026 earnings power; worst case $7 EPS at 10x = $70 (only 17% below current price)
• Dividend sustainability: 43% payout ratio ($3.4B dividends / $7.81B FCF); yield lift is mechanical from price decline, not cash flow deterioration
• UNH playbook is working operationally: insurance margin expansion, raised guidance, Ascension Arizona Medicaid acquisition, dual-eligible growth vector
• Stop at $86.57 is less than 1 ATR from current price (ATR $2.22); needs widening to 2 ATR below entry
• Waiting for bounce to $89.80-$93.19 zone is not guaranteed; price may chop sideways or grind lower
• Conservative framework means reducing position size for capital protection, not making market timing calls on specific price targets

→ vs aggressive: Dismissed $8.53 forward EPS anchor as fiction, but Q2 2026 actuals ($2.31 EPS, +7.3% revenue) prove 2026 earnings power is real and in the bank

→ vs aggressive: Dividend cut warning is wrong: 43% payout ratio on FCF ($3.4B / $7.81B) shows dividend coverage is improving, not deteriorating

→ vs aggressive: UNH playbook dismissal ignores that operational improvements are already visible in Q2 results; Aetna margin rebuild is internal operational lever, not macro trade

→ vs aggressive: Market timing call to wait for flush to high sixties or seventies is not conservative; assumes knowledge of bottom location

→ vs aggressive: Treating 2027 uncertainty as binary (nothing-burger vs catastrophic) ignores probabilistic scenarios where stock still has value

→ vs neutral: Holding full position in broken name below 200 SMA with deteriorating MACD is not balanced, it's complacency; must defend against specific chart risks

Reduce exposure by approximately 35%, executed flexibly rather than at a specific zone; sell more aggressively if price reaches $89-$90, sell into stability above $85 if drifting/chopping; protect residual with stop at $82.50 (below 2024 support near $80); stay engaged with Q3 earnings catalyst in October/November rather than fully exiting

• Q2 earnings of $2.31, 7.3% YoY revenue growth, and $5.65 billion FCF in Q2 are ledger entries, not aspirational
• 2027 opacity creates discount but doesn't invalidate 2026 earnings power already being delivered
• Worst-case 2027 EPS of $7 at 10x multiple implies $70 (17% downside), not $58-$60 (50% collapse)
• Confirmed close below 200 SMA on daily candle represents regime change, not merely a correction
• Dividend sustainability holds with 43% FCF payout ratio and FCF inflecting upward in 2026
• Neither analyst addresses position protection via hedges or hard invalidation levels
• Neither analyst addresses whether CVS should be same portfolio size on October 1 as August 1 regardless of trade action
• PBM regulatory pressure and Medicare Advantage reimbursement compression are structural headwinds being underweighted
• MACD still accelerating lower confirms downtrend is not over

→ vs aggressive: Conflates 2027 uncertainty with collapse; $58-$60 downside target is 2024 lows, not a fundamental target; selling nightmare scenario as base case is doomerism, not balanced analysis; correct that buying here is wrong but misses the operational story validity

→ vs conservative: Soft on what technical breakdown means (regime change, not correction); suggesting stop at $83.50-$84 admits more downside risk than acknowledged; 'trim 25% now and 25% on strength above $87' is just market timing in smaller increments; criticized aggressive analyst for selling into specific zone then proposes selling into different specific zone; correct on dividend math but wrong to maintain meaningful exposure in confirmed downtrend